Aethlon Medical, Inc. is a development stage therapeutic device company focused on expanding the applications of its Hemopurifier platform technology, which is designed to reduce the presence of infectious viruses and other toxins from human blood. In this regard, the Company's core focus is the development of therapeutic devices that treat HIV/AIDS (Human Immunodeficiency Virus/Acquired Immune-Deficiency Syndrome), Hepatitis-C virus (HCV) and pathogens targeted as potential biological warfare agents. In pre-clinical testing, it has published that the Company's HIV-Hemopurifier removed 55% of HIV from human blood in three hours and in excess of 85% of HIV in 12 hours. Additionally, the HIV-Hemopurifier captured 90% of gp120, a toxic protein that depletes human immune cells, during a one-hour pre-clinical blood study. It has also published pre-clinical blood studies of its HCV-Hemopurifier, which documented the ability to capture 58% of the HCV from infected blood in two hours.